Pharmacologically, nilotinib was measured in the CSF and plasma of AD patients at the 150 mg daily dosage (Cmax: 3.46 nM and 1099 nM, respectively) and the 300 mg daily dosage (Cmax: 4.7 nM and 1410 nM, respectively), suggesting a linearly proportional increase to dose in the brain [33] that would be sufficient to inhibit DDR1 (IC50 1 nM). The gene discussed is DDR1; the disease is Alzheimer disease.